Studies Support Combined SGLT2 Inhibitor and GLP-1 Therapy for Type 2 Diabetes Management
New clinical evidence demonstrates that combining SGLT2 inhibitors with GLP-1 receptor agonists provides additive benefits for type 2 diabetes patients, while machine learning tools help personalize therapy selection.
A randomized controlled trial has demonstrated that people with type 2 diabetes using continuous glucose monitoring technology achieved better glucose outcomes than those using traditional fingersticks, even when already receiving advanced therapies including SGLT2 inhibitors or GLP-1 receptor agonists. The FreeDM2 trial, conducted across 24 clinical sites in the UK and involving 303 participants, showed that at four months, participants using an Abbott FreeStyle Libre system had a significantly greater reduction in HbA1c (0.6%; p<0.001) than the group using traditional finger sticks. They also spent about 2.5 more hours a day (10.4% increase) in a healthy glucose range (70–180 mg/dL).
About 63 million people worldwide rely on insulin to manage type 2 diabetes, but real-world studies show only 18%–30% of those using basal insulin are reaching their HbA1c goals. This gap contributes to an estimated $217 billion in annual diabetes healthcare costs, indicating millions of people still need support to reach healthy glucose ranges.
SGLT2 inhibitors were first introduced as glucose-lowering medications. However, clinical trials quickly revealed broader benefits. Studies such as EMPA-REG OUTCOME and DAPA-HF demonstrated meaningful reductions in heart failure hospitalization and kidney disease progression. Unlike many traditional medications, these agents work independently of insulin. They reduce glucose by increasing urinary glucose excretion. They lower intraglomerular pressure and promote natriuresis, providing measurable protection for both the heart and kidneys, even when glycemic targets are achieved.
GLP-1 receptor agonists, including semaglutide and liraglutide, provide strong A1C reduction along with significant weight loss. Cardiovascular outcome trials such as LEADER and SUSTAIN-6 confirmed reductions in major adverse cardiovascular events. However, GLP-1 receptor agonists primarily reduce atherosclerotic events. In contrast, SGLT2 inhibitors demonstrate stronger and more consistent benefits for heart failure and chronic kidney disease progression.
Growing research supports combining SGLT2 inhibitors with GLP-1 receptor agonists in appropriate patients. Because each drug class acts through distinct mechanisms, their metabolic and cardiovascular effects can be additive. Clinical studies show greater A1C reductions when both agents are used together. Furthermore, patients often experience enhanced weight loss and modest additional blood pressure improvements. Importantly, the risk of hypoglycemia remains low since neither class directly stimulates insulin secretion.
A machine learning model developed from the China Metabolic Analytics Project analyzed 24,322 patients in the derivation dataset and 1,459 in the validation dataset to guide personalized selection between SGLT-2i and GLP-1RA therapies. The TiP DecScore used gradient boosting decision tree and 15 features, showing good predictive performance with the receiver operating characteristic curve 0.71-0.78. The derivation cohort had mean age 53.7 years, with 63.0% males.
At 6 months, compared with SGLT-2i, GLP-1RA was prioritized for patients with a shorter diabetes duration and higher fasting C-peptide, alanine aminotransferase, body mass index, and low-density lipoprotein cholesterol levels. At 12 months, patients with higher baseline HbA1c and BMI levels were more likely to be recommended GLP-1RA than SGLT-2i. Higher rates of HbA1c control were observed in concordant versus discordant groups, especially in younger patients (<55 years; 64.1% vs. 46.2%, P = 0.001) and males (58.6% vs. 45.6%, P = 0.018) at 12 months.
Patients with heart failure with reduced ejection fraction should receive an SGLT2 inhibitor promptly, even if they are already on GLP-1 therapy. Similarly, individuals with chronic kidney disease and albuminuria may benefit from early SGLT2 initiation regardless of baseline A1C levels. Meanwhile, patients with obesity and established atherosclerotic cardiovascular disease often begin with GLP-1 therapy.
A separate interventional study from Italy followed 88 adults with type 2 diabetes using basal insulin in everyday clinical practice with an Abbott FreeStyle Libre system. After 3 months, participants had better average glucose levels, more time in a healthy glucose range, and improved quality of life.